Key points are not available for this paper at this time.
Rheumatoid arthritis patients receiving anti-TNFalpha agents may develop glomerulonephritis via the induction of rheumatoid arthritis-related nephropathy or de novo autoimmune disorders.
Stokes et al. (Tue,) studied this question.